Published in Biochem J on June 01, 1999
Position and distance specificity are important determinants of cis-regulatory motifs in addition to evolutionary conservation. Nucleic Acids Res (2007) 1.28
Regulation of DYT1 gene expression by the Ets family of transcription factors. J Neurochem (2008) 0.80
Microsatellite polymorphisms associated with human behavioural and psychological phenotypes including a gene-environment interaction. BMC Med Genet (2017) 0.75
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science (1989) 25.68
Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins. Nature (1985) 14.41
Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell (1984) 9.47
Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5' flanking elements. Science (1985) 8.44
A simple phase-extraction assay for chloramphenicol acyltransferase activity. Gene (1988) 8.40
Helical repeat of DNA in solution. Proc Natl Acad Sci U S A (1979) 5.90
Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res (1992) 5.35
The complexities of eukaryotic transcription initiation: regulation of preinitiation complex assembly. Trends Biochem Sci (1991) 5.11
Requirement of stereospecific alignments for initiation from the simian virus 40 early promoter. Nature (1986) 4.77
Cooperativity of the glucocorticoid receptor and the CACCC-box binding factor. Nature (1988) 3.69
Deficiency of protein C in congenital thrombotic disease. J Clin Invest (1981) 3.56
The basics of basal transcription by RNA polymerase II. Cell (1994) 3.20
Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med (1984) 2.26
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature (1990) 1.68
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet (1983) 1.53
The transcriptional activator hepatocyte nuclear factor 6 regulates liver gene expression. Mol Cell Biol (1996) 1.50
The protein C anticoagulant pathway. Arterioscler Thromb (1992) 1.44
Regulation of blood coagulation by the protein C system. FASEB J (1992) 1.35
Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4. J Biol Chem (1996) 1.21
Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A (1986) 1.14
Distance-dependent interactions between basal, cyclic AMP, and thyroid hormone response elements in the rat growth hormone promoter. J Biol Chem (1993) 1.05
Rat growth hormone gene expression. Both cell-specific and thyroid hormone response elements are required for thyroid hormone regulation. J Biol Chem (1988) 0.93
Structure-function analysis of the rat prolactin promoter: phasing requirements of proximal cell-specific elements. Mol Endocrinol (1991) 0.87
Type I protein C deficiency caused by disruption of a hepatocyte nuclear factor (HNF)-6/HNF-1 binding site in the human protein C gene promoter. J Biol Chem (1998) 0.85
Transcriptional regulation of the gene coding for human protein C. J Biol Chem (1996) 0.83
Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. J Biol Chem (1995) 0.82
Disruption of a binding site for hepatocyte nuclear factor 1 in the protein C gene promoter is associated with hereditary thrombophilia. Hum Mol Genet (1994) 0.77
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 4.11
Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature (1984) 3.06
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood (1995) 2.96
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood (1997) 2.15
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The putative factor IX gene promoter in hemophilia B Leyden. Blood (1988) 1.98
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut (1999) 1.94
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer (1985) 1.74
Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost (1998) 1.71
Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem (2001) 1.69
Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int (1980) 1.65
Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke (1998) 1.63
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene (1987) 1.60
Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) (1985) 1.58
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost (1996) 1.58
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Genetics of venous thrombosis. J Thromb Haemost (2009) 1.54
Haemophilia B: database of point mutations and short additions and deletions--eighth edition. Nucleic Acids Res (1998) 1.54
Hereditary protein S deficiency: clinical manifestations. Ann Intern Med (1987) 1.53
Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost (2005) 1.50
Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993. Nucleic Acids Res (1993) 1.49
Recessive inheritance of von Willebrand's disease type I. Lancet (1993) 1.47
Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem (1997) 1.46
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood (2000) 1.45
Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Nucleic Acids Res (1996) 1.44
Analysis of a positional candidate gene for inflammatory bowel disease: NRAMP2. Inflamm Bowel Dis (2000) 1.44
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS). Thromb Haemost (1994) 1.41
Genetic risk factors of venous thrombosis. Hum Genet (2001) 1.40
Instability of repeats of the von Willebrand factor gene variable number tandem repeat sequence in intron 40. Br J Haematol (1993) 1.39
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol (1996) 1.39
Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost (1982) 1.37
Haemophilia B: database of point mutations and short additions and deletions--third edition, 1992. Nucleic Acids Res (1992) 1.36
Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A (2009) 1.35
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost (2004) 1.33
Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol (2001) 1.33
Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood (1985) 1.33
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost (2007) 1.32
Procoagulant activity of endocardial vegetations and blood monocytes in rabbits with Streptococcus sanguis endocarditis. Thromb Haemost (1989) 1.31
Determination of plasma protein S--the protein cofactor of activated protein C. Thromb Haemost (1985) 1.31
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci U S A (1992) 1.29
Haemophilia B: database of point mutations and short additions and deletions--second edition. Nucleic Acids Res (1991) 1.29
Prevalence of protein C deficiency in the healthy population. Thromb Haemost (1995) 1.28
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood (1994) 1.27
Genetic variants associated with deep vein thrombosis: the F11 locus. J Thromb Haemost (2009) 1.24
Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994. Nucleic Acids Res (1994) 1.21
Haemophilia B: database of point mutations and short additions and deletions. Nucleic Acids Res (1990) 1.20
Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost (2009) 1.19
The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost (1989) 1.19
Recurrent venous thrombosis and markers of inflammation. Thromb Haemost (2000) 1.18
APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum (1980) 1.18
The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood (2000) 1.18
Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol (2006) 1.18
Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol (1997) 1.17
The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost (1984) 1.17
Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis. Infect Immun (1994) 1.17
The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J (1990) 1.17
Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost (1999) 1.17
Hemophilia B Leyden: a sex-linked hereditary disorder that improves after puberty. N Engl J Med (1982) 1.16
Tetranucleotide repeat polymorphism in the vWF gene. Nucleic Acids Res (1990) 1.14
Two genes homologous with human protein S cDNA are located on chromosome 3. Thromb Haemost (1987) 1.14
Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost (2005) 1.14
An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood (1997) 1.14
Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost (1983) 1.13
Protein C deficiency in two Austrian families. Thromb Haemost (1983) 1.12
Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. Eur J Biochem (1987) 1.10
Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leyden phenotype). Blood (1989) 1.09
ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost (2005) 1.08
Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol (1995) 1.08
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Thromb Haemost (1997) 1.07
Considerations on the true value of the international normalized ratio in the control of oral anticoagulant therapy. Br J Haematol (1994) 1.07
The binding of aurovertin to mitochondria, and its effect on mitochondrial respiration. Biochim Biophys Acta (1973) 1.06
Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost (1985) 1.06
Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution. Biochemistry (1990) 1.05
Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood (1990) 1.05